Cargando…

Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes

Accumulation of advanced glycation end‐products (AGEs) is thought to contribute to muscle weakness in a diabetic animal model. Skin autofluorescence is a proposed marker for accumulation of AGEs in the skin. We aimed to investigate the relationship between AGEs accumulation, sarcopenia and muscle fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Hiroyasu, Kuroda, Akio, Araki, Michiko, Suzuki, Reiko, Taniguchi, Satoshi, Tamaki, Motoyuki, Akehi, Yuko, Matsuhisa, Munehide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415451/
https://www.ncbi.nlm.nih.gov/pubmed/27727515
http://dx.doi.org/10.1111/jdi.12582
_version_ 1783233517719650304
author Mori, Hiroyasu
Kuroda, Akio
Araki, Michiko
Suzuki, Reiko
Taniguchi, Satoshi
Tamaki, Motoyuki
Akehi, Yuko
Matsuhisa, Munehide
author_facet Mori, Hiroyasu
Kuroda, Akio
Araki, Michiko
Suzuki, Reiko
Taniguchi, Satoshi
Tamaki, Motoyuki
Akehi, Yuko
Matsuhisa, Munehide
author_sort Mori, Hiroyasu
collection PubMed
description Accumulation of advanced glycation end‐products (AGEs) is thought to contribute to muscle weakness in a diabetic animal model. Skin autofluorescence is a proposed marker for accumulation of AGEs in the skin. We aimed to investigate the relationship between AGEs accumulation, sarcopenia and muscle function of Japanese patients with type 1 diabetes. A total of 36 patients with type 1 diabetes participated in the present cross‐sectional study. Sarcopenia parameters (skeletal muscle mass index and knee extension strength) were compared with subcutaneous AGEs accumulation using skin autofluorescence. The prevalence of sarcopenia and impaired knee extension strength was 16.6% (men 0.0%, women 22.2%) and 47.2% (men 22.2%, women 55.6%), respectively. Knee extension strength was negatively correlated with skin autofluorescence (r² = 0.14, P < 0.05), but not with skeletal muscle mass index. In conclusion, the AGEs accumulation might be one of the reasons of impaired lower limb muscle function in Japanese patients with type 1 diabetes.
format Online
Article
Text
id pubmed-5415451
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54154512017-05-04 Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes Mori, Hiroyasu Kuroda, Akio Araki, Michiko Suzuki, Reiko Taniguchi, Satoshi Tamaki, Motoyuki Akehi, Yuko Matsuhisa, Munehide J Diabetes Investig Articles Accumulation of advanced glycation end‐products (AGEs) is thought to contribute to muscle weakness in a diabetic animal model. Skin autofluorescence is a proposed marker for accumulation of AGEs in the skin. We aimed to investigate the relationship between AGEs accumulation, sarcopenia and muscle function of Japanese patients with type 1 diabetes. A total of 36 patients with type 1 diabetes participated in the present cross‐sectional study. Sarcopenia parameters (skeletal muscle mass index and knee extension strength) were compared with subcutaneous AGEs accumulation using skin autofluorescence. The prevalence of sarcopenia and impaired knee extension strength was 16.6% (men 0.0%, women 22.2%) and 47.2% (men 22.2%, women 55.6%), respectively. Knee extension strength was negatively correlated with skin autofluorescence (r² = 0.14, P < 0.05), but not with skeletal muscle mass index. In conclusion, the AGEs accumulation might be one of the reasons of impaired lower limb muscle function in Japanese patients with type 1 diabetes. John Wiley and Sons Inc. 2016-11-23 2017-05 /pmc/articles/PMC5415451/ /pubmed/27727515 http://dx.doi.org/10.1111/jdi.12582 Text en © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Mori, Hiroyasu
Kuroda, Akio
Araki, Michiko
Suzuki, Reiko
Taniguchi, Satoshi
Tamaki, Motoyuki
Akehi, Yuko
Matsuhisa, Munehide
Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
title Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
title_full Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
title_fullStr Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
title_full_unstemmed Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
title_short Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
title_sort advanced glycation end‐products are a risk for muscle weakness in japanese patients with type 1 diabetes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415451/
https://www.ncbi.nlm.nih.gov/pubmed/27727515
http://dx.doi.org/10.1111/jdi.12582
work_keys_str_mv AT morihiroyasu advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT kurodaakio advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT arakimichiko advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT suzukireiko advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT taniguchisatoshi advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT tamakimotoyuki advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT akehiyuko advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes
AT matsuhisamunehide advancedglycationendproductsareariskformuscleweaknessinjapanesepatientswithtype1diabetes